The University of MichiganNews Services
The University Record Online
Updated 5:30 PM September 5, 2007




view events

submit events

UM employment

police beat
regents round-up
research reporter


Advertise with Record

contact us
meet the staff
contact us
contact us

Newborn screening procedure revives old controversy

In 1961 Robert Guthrie developed a method to test newborns for phenylketonuria, or PKU — a genetic disorder that prevents the body from processing a protein found in almost all food, causing severe mental retardation.

Now using just one drop of blood, about 4 million newborns in the United States undergo testing through state screening programs each year for PKU, as well as a number of other genetic diseases including sickle cell disease and cystic fibrosis. And promising new DNA-based technology is on the horizon that greatly will expand the medical community's ability to detect more genetic abnormalities in newborns.

This new technology also has rekindled a debate that has plagued newborn screening for more than 40 years: lack of federal mandates for testing, the costs of long-term treatment for children who test positive for a genetic disorder and testing for diseases that may have a potential treatment but no cure, among others.

In a paper published in the August issue of the Archives of Pediatric & Adolescent Medicine, lead author Dr. Beth Tarini, clinical lecturer and member of the Child Health Evaluation Research Unit at C.S. Mott Children's Hospital, outlines the controversies surrounding newborn screening, and provides insight into the issues that must be addressed for the continued success of this public health screening program.

"Given the rapid pace of technological advancements, we must make clear and informed decisions about how we implement new technology in state newborn screening programs," Tarini says. "Many questions remain about screening uniformity and how best to coordinate follow-up evaluation for positive newborn screening tests."

Although all 50 states mandate newborn screening, the specific genetic conditions screened and testing methods often vary from state to state. Some states test for the 29 conditions recommended by the American College of Medical Genetics. Other states, including Michigan, test for more than 40 conditions, Tarini says.

"Uniformity with newborn screening is key in terms of assuring equal access and establishing a standard of care," Tarini says. "But then the issue becomes how high do you set the bar? Do you only test for 29 genetic disorders, or should newborns be tested for 40?"

New technology is pushing these issues to the forefront. With only one drop of blood, tandem mass spectrometry — a technology that medical experts first applied to newborn screening in the 1990s — can detect at least four times more disorders than previous testing techniques.

Another recently developed technological advance — DNA microarray — offers the potential to continue to broaden newborn screening by making it possible to test for hundreds of potential disease-causing genetic mutations.

But the process of newborn screening involves more than the initial blood test.

A successful public health screening program is not complete without proper follow-up care, and should include a systematic collection of long-term data to advance medical research and treatment of genetic disorders, Tarini says.

"In our society, technology drives us — and medicine is no different. However, healthcare providers and public health officials are in a position to make decisions about how we implement technology in a way that maximizes health benefits for the child, and minimizes any harm, even if it is unintentional," she says.

To ensure the continued success of newborn screening, Tarini says there needs to be improved communication between health care providers and parents prior to and following screening, as well as coordination of care between primary care physicians and genetic experts for infants with positive screening results.

More Stories